Emily Elizabeth Devine
My passion for the multidisciplinary field of health economics and outcomes research is motivated by my desire to ensure that we, as scientists, provide the best value for investments made – for our individual patients, for populations under our care, and for the health(care) sector of society.
I am particularly passionate about applying the most rigorous and appropriate study designs and analytic methods to accurately answer relevant questions in the areas of comparative effectiveness of health technologies, precision medicine in the context of clinical informatics, and patient centered outcomes. To do so, I employ methods at the intersection of evidence synthesis and decision modeling.
I am also passionate about training the next generation of scientists in Health Economics and Outcomes Research
I am a tenured Professor in the School of Pharmacy, University of Washington (UW). I am honored to hold the Shirley and Herb Bridge Endowed Professor for Women in Pharmacy. I hold adjunct appointments in the Departments of Health Services and Biomedical Informatics; and am a member of the Institute for Public Health Genetics and the Plein Center for Geriatric Pharmacy Research.
I had the privilege of being a Fulbright US Senior Scholar (Fall 2021), Department of Health Services Research in Preventive Medicine, University of Murcia, Murcia, España.
And a Visiting Professor (January-June 2022), Department of Health Services Research in Preventive Medicine, University of Murcia, Murcia, España.
I am a member of the Board of Directors of ISPOR-the leading professional society for Health Economics and Outcomes Research, an Associate Editor for the ISPOR journal Value in Health, and a member of the Academy Health Methods and Data Council.
I am an Assistant Director of the AHRQ-funded Pacific Northwest Evidence-based Practice Center, an elected member of the Society for Research Synthesis Methodology and served on the ISPOR Task Force that developed guidelines to conduct network meta-analyses.
Prior to joining the faculty at the UW, I was an advanced practice (prescribing) clinical pharmacist and formulary lead at the University of California San Francisco, where I served a term as president of the California Society of Health-System Pharmacists, earning their Lifetime Achievement Award for my leadership role in advancing the scope of practice for California pharmacists through legislation (1994).
Research Program Summary
Health economics and outcomes research is a multidisciplinary field that employs methods from the overlapping disciplines of epidemiology, biostatistics, decision sciences, health economics and health policy.
Trained in both health services research and health economics, I focus on the following areas of research, I:
1. Apply my expertise to evidence synthesis projects, where I conduct systematic reviews and employ Bayesian and frequentist methods to conduct network meta-analyses and meta-analyses.
Saldanha IJ, Adam GP, Bañez LL, Bass EB, Berliner E, Devine B, et al. Inclusion of nonrandomized studies of interventions in systematic reviews of interventions: Updated guidance from the Agency for Healthcare Research and Quality Effective Healthcare Program. (in press at J Clin Epi, August 2022)
Lee, W, Schwartz N, Bansal S, Khor S, Hammarlund N, Basu A, Devine B. A Scoping Review of the Use of Machine Learning in Health Economics and Outcomes Research: Part 1 – Data from Wearable Devices, (in press at Value Health, May 2022)
Lee, 9W, Schwartz N, Bansal S, Khor S, Hammarlund N, Basu A, Devine B. A Scoping Review of the Use of Machine Learning in Health Economics and Outcomes Research: Part 2 – Data from non-Wearables. (in press at Value Health, July 2022)
Quach D, Jiao B, Basu A, Bender MA, Hankins J, Ramsey S, Devine B. A landscape analysis and discussion of value of gene therapies for sickle cell disease. Expert Rev Pharmacoecon Outcomes Res 2022 Apr 18:1-21. doi: 10.1080/14737167.2022.2060823. Online ahead of print.PMID: 35363602
Dhippayom T, Boonpattharatthiti K, Thammathuros T, Dilokthornsakul P, Sakunrag I, Devine B. Clinical Outcomes of Different Warfarin Self-Care Strategies: A Systematic Review and Network Meta-Analysis. Thromb Haemost. 2022;122:492-505.
Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Devine B. Medical and non-medical costs of sickle cell disease, treatments, and related complications: A Systematic Review and Landscape Analysis. PharmacoEconomics Open 2022 Apr 26. Pharmacoecon Open. 2022 Apr 26. doi: 10.1007/s41669-022-00330-w. Online ahead of print.PMID: 35471578
Jiao B, Baldwin Z, Basu A, Roth J, Bender MA, Devine B. Health State Utilities for Sickle Cell Disease: A Systematic Review and Landscape Analysis. (in press at Value Health, August 2021)
Lee W, Cheng S, Grant SJ, Marcum ZA, Devine B. Use of Geriatric Assessment in Cancer Clinical Trials: A Systematic Review. (in press at J Geriatric Onc, May 2022)
Jiao B, Baldwin Z, Basu A, Roth J, Bender MA, Devine B. Estimates of the Cost-effectiveness of Screening and Treatments for Sickle Cell Disease: A Systematic Review and Landscape Analysis. PharmacoEconomics 2021;39:1225-1241
Duchowny M, Chopra I, Niewoehner J, Wan GJ, Devine B. Comparative Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms. J Health Econ Outcomes Res, 2021 Jan 27;8(1):1-9.
Dhippayom T, Saensook T, Promkhatja N, Teakthong T, Chaiyakunapruk N, Devine B. Comparative effects of music intervention on depression in older adults: A systematic review and network meta-analysis. (in press at eClinical Medicine, May 2022)
2. Explore the effectiveness of pharmacogenomic and genomic biomarker-guided medication use on clinical
outcomes, using real world evidence in the context of clinical informatics and electronic health record data.
Devine EB, Boyce R, Wiisanen K (eds). Clinical Decision Support for Pharmacogenomic Precision Medicine. Elsevier, 2022.
Boyce RD, Camacho J, Liang W, Wiisanen K, Devine B. Overview of effective pharmacogenomic clinical decision support. In: Devine B, Boyce RD, Wiisanen K (eds). Clinical Decision Support for Pharmacogenomic Precision Medicine. Elsevier, 2022.
Angelo F, Veenstra D, Knerr S, Devine B. Prevalence and prediction of medical distrust in a diverse medical genomic research sample. Genet Med. 2022 Apr 6;S1098-3600(22)00697-9. doi: 10.1016/j.gim.2022.03.007. Online ahead of print.
Knerr S, Guo B, Mittendorf KF, Goddard KAB, Devine EB and the CHARM Study Team. Risk-reducing surgery in unaffected women receiving cancer genetic testing in an integrated healthcare system. 2022 Jun 9. doi: 10.1002/cncr.34349. Online ahead of print.PMID: 35679147.
Jiang S, Mathias, Hendrix N, Shirts B, Veenstra DL, Malone D, Devine B. Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. Pharmacogenomics J. 2022 Apr 1. doi: 10.1038/s41397-022-00275-7. Online ahead of print.PMID: 35365779
Chaitesipaseut L, Wilson-Norton J, Trivelli K, Mikes T, Devine B. Feasibility of conducting pharmacogenomic-guided medication therapy management in retirement communities. J Am Coll Clin Pharm, 21 November 2021. https://doi.org/10.1002/jac5.1570
3. Address decision problems in health technology assessment and outcomes research including preference-
based methods, discrete choice experiments and multi-criteria decision analysis.
Saldarriaga EM, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine, B. Assessing payers’ preferences for real world evidence: A discrete choice experiment. Value Health 2022;25:443-450. (Editor´s Choice)
Lee D, Kim Y, Devine B. Spillover effects of mental disorders on family members’ utility: SF-6D scores from a US sample. 2021 Aug 11:272989X211027146. doi: 10.1177/0272989X211027146. Online ahead of print. PMID: 34378438
Hendrix N, Kim DD, Patel KS, Devine B. Differences in the selection of health state utility values by sponsorship in published cost-effectiveness analyses. Med Decis Making. 2021 Apr;41(3):366-372. doi: 10.1177/0272989X20985821. Epub 2021 Jan 15.
Chen S, Yun S, Graf J, Beal B, Bansal A, Carlson J, Basu A, Devine B. The REAdi (Real-World Evidence Assessments and Needs Guidance) Tool: A Framework for Evaluating Real-World Evidence. J Manag Care Spec Pharm. 2021 Jan;27(1):95-104. doi: 10.18553/jmcp.2021.27.1.095.
Jiao B, Veenstra D, Lee W, Carlson J, Devine B. The use of real-world evidence in ICER’s scoping process and clinical evidence assessment. J Manag Care Spec Pharm. 2020 Dec;26(12):1590-1595. doi: 10.18553/jmcp.2020.26.12.1590.
My work is funded by the US Agency for Healthcare Research and Quality. I also lead projects funded by the NIH (National Cancer Institute; National Heart, Lung and Blood Institute; National Institute on Aging) and the US Department of Veterans Affairs. I am currently a co-investigator on the Electronic Medical Records and Genomics (eMERGE 4) Network and the Clinical Sequencing Evidence-Generating Research (CSER 2), both national consortia funded by the NIH-National Human Genome Research Institute.
I teach methods courses on the UW Health Sciences campus.
Assessing Outcomes in Health and Medicine (for PhD students in Health Sciences).
Fundamentals of biostatistics and epidemiology to facilitate critical literature evaluation (for Doctor of Pharmacy students).
Health Technology Assessment. UW Distance Learning Program in Health Economics and Outcomes Research.
Principles of Data Science. UW Distance Learning Program in Health Economics and Outcomes Research (in development, 2022).
Primary Academic Appointment
Professor, The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute
Shirley and Herb Bridge Endowed Professor for Women in Pharmacy
School of Pharmacy, University of Washington
Fulbright Scholar (Fall 2021)
Visiting Professor (Winter/Spring 2022)
University of Murcia, Murcia, Spain
Adjunct Academic Appointments
Adjunct, Department of Health Services, School of Public Health
Adjunct, Department of Biomedical Informatics, School of Medicine
Member, Institute for Public Health Genetics
Member, Plein Institute for Geriatric Pharmacy Practice
Administrative Academic Appointments
Associate Director, The CHOICE Institute
School of Pharmacy, University of Washington
Selected Honors & Awards
Visiting Professor, University of Murcia, Murcia, España
Fulbright Senior Scholar, University of Murcia, Murcia, España (Fall)
Nominated for the UW-wide Marsha L. Landolt Distinguished Graduate Mentor of the Year Award
2021 - 2024
Elected member, ISPOR Board of Directors
2021 - 2025
Associate Editor, Value in Health
Guest Editor, Theme section on Remote Patient Monitoring, Value in Health
Nominated for Faculty Mentor of the Year Award, UW School of Pharmacy (June)
Nominated for Institute of Medicine Anniversary Pharmacy Fellowship
Elected member, Society for Research Synthesis Methodology
Member, Beta Gamma Sigma National Business Honor Society
Fellow, American Society of Health-System Pharmacists
Pharmacist of the Year Lifetime Achievement Award, California Society of Health-System Pharmacists
Member, Phi Lambda Sigma, Pharmacy Leadership Society
Education & Training
2005 - 2008
PhD in Health Services Research, Dept of Health Services, School of Public Health, UW, Seattle WA Dissertation: “Evaluating the impact of an ambulatory computerized provider order entry system on outcomes in a community-based multispecialty health system”
1999 - 2001
Post-doctoral Fellowship in Pharmacoeconomics and Outcomes Research, UW, Seattle, WA and Roche Global Pharmacoeconomics, Palo Alto, CA
1997 - 1999
Master in Business Administration, Masagung Graduate School of Business and Management, University of San Francisco, San Francisco, CA Thesis: “UCSF Pharmacy Faculty Practice Consortium: A plan for optimizing medication use in physician group practices”
1978 - 1979
Clinical Pharmacy Residency, Veterans Administration Health Care System, Palo Alto, CA
1975 - 1978
Doctor of Pharmacy degree, University of the Pacific, Stockton, CA
1973 - 1975
Pre-pharmacy, University of the Pacific, Stockton, CA Music minor, Conservatory of Music, University of the Pacific, Stockton, CA